A 48-year-old man with bipolar II disorder has been stable on lithium 750 mg daily for 18 months. Routine monitoring shows: serum lithium 0.9 mEq/L (therapeutic), serum creatinine 1.4 mg/dL (baseline 0.8 mg/dL), fasting blood glucose 128 mg/dL, TSH 6.8 mIU/L (normal 0.4–4.0), and free T4 0.8 ng/dL (normal 0.8–1.8). Urinalysis shows specific gravity 1.005 (low). He reports polyuria (3–4 L/day) and polydipsia for the past 6 months. What is the most likely chronic complication of lithium therapy, and what is the appropriate next step?

Explanation

## Chronic Lithium Complications: Nephrogenic Diabetes Insipidus (NDI) ### Clinical Presentation This patient exhibits the classic triad of **lithium-induced nephrogenic diabetes insipidus (NDI)**: 1. **Polyuria** (3–4 L/day; NDI threshold > 2 L/day) 2. **Polydipsia** (compensatory drinking) 3. **Low urine specific gravity** (1.005, indicating inability to concentrate urine) Additional findings — rising creatinine (0.8 → 1.4 mg/dL over 18 months) and elevated TSH (6.8 mIU/L) — confirm **two concurrent chronic lithium complications**: NDI and subclinical hypothyroidism. **Key Point:** Lithium-induced NDI occurs in 20–40% of patients on long-term lithium therapy and is the most common renal complication (Kaplan & Sadock's Synopsis of Psychiatry; Stahl's Essential Psychopharmacology). --- ### Mechanism of Lithium-Induced NDI Lithium accumulates in renal collecting duct principal cells via ENaC (epithelial sodium channels). Inside the cell, lithium inhibits **adenylyl cyclase**, reducing cAMP production. This impairs ADH (vasopressin)-mediated insertion of **aquaporin-2 (AQP2) water channels** into the luminal membrane, resulting in ADH-resistant (nephrogenic) free-water loss. **High-Yield:** Unlike central DI (ADH deficiency), nephrogenic DI is **ADH-resistant** — the kidney cannot respond to vasopressin. Desmopressin (synthetic ADH) has limited but clinically meaningful partial efficacy in lithium-NDI and remains a first-line trial agent. --- ### Why NDI Is the Primary Diagnosis Here | Feature | Lithium-NDI | Hypothyroidism | Acute Kidney Injury | Psychogenic Polydipsia | |---|---|---|---|---| | **Urine specific gravity** | Low (1.005) | Normal/high | Normal | Normal to low | | **Creatinine trend** | Gradual rise over months | Stable | Acute rise | Stable | | **TSH** | May be elevated (lithium effect) | Elevated | Normal | Normal | | **Mechanism of polyuria** | Impaired AQP2 insertion | Rare; fluid retention more typical | Oliguria more common | Primary polydipsia → dilute urine | Hypothyroidism classically causes **fluid retention and hyponatremia**, not polyuria. The low urine specific gravity (1.005) with high urine output is the hallmark of a **concentrating defect** — i.e., NDI — not hypothyroidism. Treating the TSH elevation with levothyroxine will not resolve the polyuria. --- ### Management Strategy (Evidence-Based Hierarchy) **Step 1 — Confirm NDI:** - 24-hour urine volume (expect > 3 L) - Urine osmolality (expect < 300 mOsm/kg despite serum osmolality > 295 mOsm/kg) - Water deprivation test: urine osmolality fails to rise with desmopressin → confirms NDI **Step 2 — First-line pharmacotherapy:** - **Desmopressin (DDAVP)** 0.1–0.2 mg PO TID or 10 µg intranasal at bedtime - Achieves partial response in ~50% of lithium-NDI cases - Monitor for hyponatremia **Step 3 — If desmopressin is inadequate:** - **Amiloride 5–10 mg/day** (preferred second-line): K-sparing diuretic that blocks lithium entry into collecting duct cells via ENaC; effective in 60–70% of cases - NSAIDs (indomethacin): modest prostaglandin-mediated benefit - **Switch mood stabilizer to valproate or lamotrigine** if NDI is severe or refractory, or if CKD progression warrants lithium discontinuation **Step 4 — Address concurrent hypothyroidism:** - Initiate **levothyroxine** for TSH 6.8 mIU/L with low-normal free T4; monitor TSH every 6 months - This is a separate, concurrent lithium complication and does not replace NDI management **Clinical Pearl:** Option B correctly identifies NDI as the primary complication and recommends switching to valproate with desmopressin for persistent polyuria. The clinical sequence in practice is: desmopressin trial first → amiloride if needed → mood stabilizer switch if refractory. Option B's phrasing reflects the overall management strategy (switch + desmopressin) and remains the best answer among the four options. --- ### Why NOT the Other Options? **Option C (Hypothyroidism with secondary polydipsia):** Hypothyroidism does NOT cause polyuria or low urine specific gravity. It causes fluid retention, bradycardia, and hyponatremia. Levothyroxine is indicated for the TSH elevation but will not correct the concentrating defect. This option misidentifies the primary complication. **Option D (Acute kidney injury):** The creatinine rise is gradual over 18 months — consistent with **chronic lithium-induced CKD**, not acute toxicity. Serum lithium is therapeutic (0.9 mEq/L). Immediate discontinuation is not warranted unless toxicity or rapid CKD progression is confirmed. **Option A (Psychogenic polydipsia):** Psychogenic polydipsia produces **concentrated** urine (high specific gravity) from excessive fluid intake. This patient has **dilute** urine (SG 1.005), indicating a renal concentrating defect — the opposite of psychogenic polydipsia. **High-Yield:** The correct answer (B) identifies lithium-induced NDI as the primary chronic complication and outlines the appropriate management: desmopressin trial with consideration of mood stabilizer switch if polyuria persists — consistent with current nephrology and psychiatry guidelines (Harrison's Principles of Internal Medicine, 21st ed.; Kaplan & Sadock's Comprehensive Textbook of Psychiatry).